Hi Matt, Stockid,
IMPH seems to be gaining momentum fast.
Not too long ago, volume of 50k seemed
like a heavy day. Lately 100k+ is becoming
the norm.
With regards to competition, i found an
article in Sept 3, 1997 Wall St. Jr. (pg B4),
that talks about Smith Kline Beecham 'forging
a joint venture, dubbed Diadexus, with U.S.
biotech star Incyte Pharmaceuticals Inc. The
venture will inherit access to two of the
world's biggest private libraries of genetic
data... That dowry includes marketing rights
to five diagnostic tests, in the areas of
cancer and bone disease...
During the venture's first few years, its
tests will be made available to physicians
primarily through SmithKline's clinical
laboratories division. SmithKline's unit,
a leading lab network in the U.S., has
struggled with anemic sales in recent years...'
Take Care,
DH |
